Omicron KP.2 Variant Adapted mRNA COVID-19 Vaccine Authorized in Canada

Pfizer Canada ULC and BioNTech SE announced today that Health Canada has authorized the KP.2 variant-adapted COMIRNATY® COVID-19 vaccine for people six months and older. 

As of September 24, 2024, the newly formulated vaccine will be available nationwide in pharmacies and vaccination centers in the fall of 2024. Each province and territory will have its pathway for accessing the vaccine, and individuals are encouraged to refer to their provincial/territorial authorities for more information.

The adapted COVID-19 vaccine will be available in Canada as a single dose for individuals five years and older, regardless of prior COVID-19 vaccination history.

For children six months through 4 years of age, COMIRNATY® is authorized for administration as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course or as a single dose for those with a history of completion of a COVID-19 primary vaccination course.

Health Canada posts a summary of COVID-19 cases, hospitalizations, and deaths across Canada as of September 24, 2024.